

VPA22033/060/001

Endofluke 100 mg/ml Oral Suspension

Variation	Summary	Date
Vet - F.III.1 a) z.	VRA-R - Vet - F.III.1 a) z. - - Vet - F.III.1 a) z. - Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur. certificate of suitability - For an active substance, For a starting material/reagent/intermediate used in the manufacturing process of the active substance, For an excipient - European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph. - Other changes under this code level, e.g. variations outlined in section 6 and 7 of this guidance	11/12/25
Vet - C1	VNRA - Vet - C1 - - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	25/08/25
Vet - C6	VNRA - Vet - C6 - - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in this Annex	25/08/25
Vet - C1	VNRA - Vet - C1 - - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	25/08/25
Vet - C6	VNRA - Vet - C6 - - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in this Annex	25/08/25
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	08/01/25
Vet - B44(Do not use)	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur.	19/09/23

	CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	
Vet - B44(Do not use)	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	19/09/23
Vet - B44(Do not use)	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	19/09/23
Vet - B44(Do not use)	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	18/09/23
Vet - B44(Do not use)	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	18/09/23
Vet - B44(Do not use)	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	18/09/23
Vet - B22	VNRA - Vet - B22 - Change to importer, batch control	13/03/23

	arrangements and quality testing (replacement or addition of a site) for a finished product - B22 Changes to the quality part of the dossier: Change to importer, batch control arrangements and quality testing (replacement or addition of a site) for a finished product	
Vet - B35 a)	VNRA - Vet - B35 a) - a) Tightening of specification limits - B35 a) Changes to the quality part of the dossier: Change in the specification parameters or limits of the immediate packaging of the finished product: — tightening of specification limits	09/06/22
Vet - B35 a)	VNRA - Vet - B35 a) - a) Tightening of specification limits - B35 a) Changes to the quality part of the dossier: Change in the specification parameters or limits of the immediate packaging of the finished product: — tightening of specification limits	08/06/22